What are the keys to making rare disease drug development sustainable?
Just as complex molecules and large‑scale commercial projects demand the highest standards, niche rare‑disease drugs do too. Taehyeong Kim, our associate director of project management, says an end‑to‑end CDMO delivers speed, quality, and sustainability—turning innovation into viable business.
Read more in the Pharma’s Almanac commentary.
Just as complex molecules and large‑scale commercial projects demand the highest standards, niche rare‑disease drugs do too. Taehyeong Kim, our associate director of project management, says an end‑to‑end CDMO delivers speed, quality, and sustainability—turning innovation into viable business.
Read more in the Pharma’s Almanac commentary.
Share article
Related Content